JP2010120964A5 - - Google Patents

Download PDF

Info

Publication number
JP2010120964A5
JP2010120964A5 JP2010036052A JP2010036052A JP2010120964A5 JP 2010120964 A5 JP2010120964 A5 JP 2010120964A5 JP 2010036052 A JP2010036052 A JP 2010036052A JP 2010036052 A JP2010036052 A JP 2010036052A JP 2010120964 A5 JP2010120964 A5 JP 2010120964A5
Authority
JP
Japan
Prior art keywords
preparation
growth factor
methylideneaminooxy
dihydronaphthalen
biodegradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010036052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010120964A (ja
JP5287761B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2010036052A priority Critical patent/JP5287761B2/ja
Priority claimed from JP2010036052A external-priority patent/JP5287761B2/ja
Publication of JP2010120964A publication Critical patent/JP2010120964A/ja
Publication of JP2010120964A5 publication Critical patent/JP2010120964A5/ja
Application granted granted Critical
Publication of JP5287761B2 publication Critical patent/JP5287761B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010036052A 2002-10-10 2010-02-22 内因性修復因子産生促進剤 Expired - Fee Related JP5287761B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010036052A JP5287761B2 (ja) 2002-10-10 2010-02-22 内因性修復因子産生促進剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2002298079 2002-10-10
JP2002298079 2002-10-10
JP2002318830 2002-10-31
JP2002318830 2002-10-31
JP2003117604 2003-04-22
JP2003117604 2003-04-22
JP2010036052A JP5287761B2 (ja) 2002-10-10 2010-02-22 内因性修復因子産生促進剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005501023A Division JP4497320B2 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤

Publications (3)

Publication Number Publication Date
JP2010120964A JP2010120964A (ja) 2010-06-03
JP2010120964A5 true JP2010120964A5 (https=) 2010-07-15
JP5287761B2 JP5287761B2 (ja) 2013-09-11

Family

ID=32096713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005501023A Expired - Fee Related JP4497320B2 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤
JP2010036052A Expired - Fee Related JP5287761B2 (ja) 2002-10-10 2010-02-22 内因性修復因子産生促進剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005501023A Expired - Fee Related JP4497320B2 (ja) 2002-10-10 2003-10-09 内因性修復因子産生促進剤

Country Status (10)

Country Link
US (3) US7547715B2 (https=)
EP (2) EP1563846B1 (https=)
JP (2) JP4497320B2 (https=)
AU (1) AU2003272963A1 (https=)
DK (2) DK2465537T3 (https=)
ES (2) ES2584606T3 (https=)
HU (1) HUE029417T2 (https=)
PT (2) PT1563846E (https=)
TW (1) TW200413000A (https=)
WO (1) WO2004032965A1 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
WO2005072743A1 (ja) * 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
WO2006103770A1 (ja) * 2005-03-30 2006-10-05 Osaka Prefectural Hospital Organization 血管新生制御方法
GB2444686B (en) * 2005-09-12 2010-08-25 Es Cell Int Pte Ltd Differentiation of pluripotent stem cells using p38 MAPK inhibitors or prostaglandins
KR20080084808A (ko) 2005-11-17 2008-09-19 바이오미메틱 세라퓨틱스, 인크. ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강
ES2443581T3 (es) 2006-02-09 2014-02-19 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US20080171972A1 (en) * 2006-10-06 2008-07-17 Stopek Joshua B Medical device package
PL2087890T3 (pl) 2006-10-19 2014-08-29 Ono Pharmaceutical Co Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki
AU2013213727B2 (en) * 2006-10-20 2016-03-17 Children's Medical Center Corporation Method to enhance tissue regeneration
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
US8410171B2 (en) * 2006-10-26 2013-04-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
WO2008073628A2 (en) 2006-11-03 2008-06-19 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
EP2269611B1 (en) 2006-11-16 2016-03-23 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
JP2008195660A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 中枢循環改善薬
AU2009212151C1 (en) 2008-02-07 2015-09-17 Stryker Corporation Compositions and methods for distraction osteogenesis
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
HRP20151443T1 (hr) * 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
BR122020000059B8 (pt) 2008-09-09 2021-06-22 Biomimetic Therapeutics Inc composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US20100267826A1 (en) * 2009-04-20 2010-10-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists
EP3167875A1 (en) * 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
EP2435049A1 (en) * 2009-05-27 2012-04-04 Sucampo AG Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
BR112012020566B1 (pt) 2010-02-22 2021-09-21 Biomimetic Therapeutics, Llc Composição de fator de crescimento derivado de plaqueta
US20120136011A1 (en) * 2010-07-30 2012-05-31 Allergan, Inc. Compounds and methods for skin repair
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
AU2012217630A1 (en) * 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) * 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
KR101937782B1 (ko) 2011-03-01 2019-01-11 파넥스트 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
ES2730410T3 (es) 2012-09-21 2019-11-11 Univ Osaka Material para el tratamiento de insuficiencia cardíaca avanzada como dispositivo de regeneración miocárdica/cardiovascular
EP2913047B1 (en) * 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9763911B2 (en) * 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
EP3569249A4 (en) 2016-12-27 2020-11-11 Osaka University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF REFRACTORY HEART DISEASE
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US20200206309A1 (en) * 2017-07-27 2020-07-02 The Mclean Hospital Corporation METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF NURR1- AND PPARy-MEDIATED CONDITIONS
EP3718537A4 (en) 2017-11-27 2021-11-10 Osaka University DISEASE-SPECIFIC LIPOSOMAL FORMULATION
JP7233087B2 (ja) * 2019-03-18 2023-03-06 公立大学法人横浜市立大学 抗動脈硬化剤
EP4051276B1 (en) 2019-10-28 2025-08-06 Seyltx, Inc. Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives
WO2021163400A1 (en) 2020-02-12 2021-08-19 Cytoagents, Inc. Compositions and methods for treating coronavirus infections
WO2021202708A1 (en) * 2020-03-31 2021-10-07 Ensysce Biosciences, Inc. Methods for treating viral infections with nafamostat
KR20220040169A (ko) * 2020-09-23 2022-03-30 (주)아이엠디팜 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (https=) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPS503362B1 (https=) 1970-06-10 1975-02-04
JPS5231404B1 (https=) 1971-04-28 1977-08-15
US3965143A (en) 1974-03-26 1976-06-22 G. D. Searle & Co. 16-Oxygenated prostanoic acid derivatives
US4132738A (en) 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
GB2017699B (en) 1978-03-31 1983-01-12 Ono Pharmaceutical Co 6,9-methano-pgi2 analogues
JPS54130543A (en) 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US4650804A (en) 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
JPS6130519A (ja) 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
JPS62134787A (ja) 1985-12-06 1987-06-17 株式会社クボタ 自動販売機の商品払出し装置
CA2100918C (en) * 1992-07-21 1997-01-21 Nobuyuki Hamanaka Oxime derivative
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JP3162668B2 (ja) 1997-02-04 2001-05-08 小野薬品工業株式会社 ω−シクロアルキル−プロスタグランジンＥ２誘導体
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP4044967B2 (ja) 1997-02-10 2008-02-06 小野薬品工業株式会社 １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
WO1999009992A1 (en) 1997-08-27 1999-03-04 Yoshitomi Pharmaceutical Industries, Ltd. Neovascularization promoters
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
DE69821987T2 (de) 1997-12-25 2004-12-16 Ono Pharmaceutical Co. Ltd. Omega-cycloalkyl-prostaglandin e2 derivate
EP1065233A1 (en) 1998-02-27 2001-01-03 Ono Pharmaceutical Co., Ltd. Carrier polymers migrating into target organs and drug-containing polymers
JP4123568B2 (ja) 1998-05-06 2008-07-23 小野薬品工業株式会社 ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
JP2000086517A (ja) * 1998-09-16 2000-03-28 Ono Pharmaceut Co Ltd アロディニア治療剤
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
WO2000021542A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
JP2000239188A (ja) 1998-12-22 2000-09-05 Mitsubishi Chemicals Corp 育毛剤
WO2000038667A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US6462080B1 (en) 1998-12-24 2002-10-08 Alcon Manufacturing, Ltd. Prostaglandin E receptor agonists for treatment of dry eye
SE9900025D0 (sv) 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
CN1304318A (zh) 1999-03-16 2001-07-18 东丽株式会社 前列腺素ep4受体作用药和治疗方法
CA2332375A1 (en) 1999-03-16 2000-09-21 Masafumi Isogaya Cervical ripening agent and cervical ripening method
AU6836200A (en) 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
AP2001002357A0 (en) 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
PT1339678E (pt) 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
GB0030541D0 (en) 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
JP4550417B2 (ja) 2001-10-23 2010-09-22 メルク セローノ ソシエテ アノニム プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物
DE60235198D1 (de) 2001-12-20 2010-03-11 Merck Serono Sa Coinsins Pyrrolidin-derivatie als prostaglandin-modulatoren
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
PL2087890T3 (pl) 2006-10-19 2014-08-29 Ono Pharmaceutical Co Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki

Similar Documents

Publication Publication Date Title
JP2010120964A5 (https=)
JP2011201907A5 (https=)
JP2011037901A5 (https=)
JP2017513836A5 (https=)
JP2012502885A5 (https=)
JP2011528658A5 (https=)
RU2573392C3 (ru) Композиция, содержащая тетрациклические соединения
JP2010077141A5 (https=)
JP2007302683A5 (https=)
JP2012533546A5 (https=)
JP2014515013A5 (https=)
JP2009523760A5 (https=)
JP2013542247A5 (https=)
JP2013518107A5 (https=)
JP2014521744A5 (https=)
JP2016511753A5 (https=)
WO2014093579A3 (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
JP2009537554A5 (https=)
JP2013529637A5 (https=)
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
JP2012512164A5 (https=)
JP2011102272A5 (https=)
WO2011129579A3 (en) Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
WO2013128419A3 (en) Pharmaceutical compositions comprising boronic acid compounds
TR201906158T4 (tr) Etken Maddeler ile Farmasötik-Teknolojik Yardımcı Maddeler Arasındaki Etkileşimleri Engellemek Amacıyla Kullanılan Farmasötik Preparatlar İçin Ayırıcı Katmanlar.